Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 2 AND POTASSIUM CHLORIDE 10MEQ versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 2 AND POTASSIUM CHLORIDE 10MEQ versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextrose provides calories and serves as a source of energy through cellular glucose uptake and metabolism. Sodium chloride replenishes extracellular fluid and electrolytes. Potassium chloride replaces intracellular potassium, essential for neuromuscular and cardiac function.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Intravenous infusion: 100-200 mL/hour, adjusting based on patient's fluid status, serum electrolytes, and clinical response. Typical administration rate for maintenance: 0.5-1.5 mL/kg/hour.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Dextrose: 1-2 hours (endogenous glucose turnover). Potassium: ~4-6 hours in healthy adults; prolonged in renal impairment.
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Renal: Dextrose is metabolized to CO2 and water; sodium and potassium are excreted renally. Potassium excretion is 90% renal, 10% fecal. Sodium excretion is >95% renal.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte